Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.
A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray \[Nasonex®\] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via Nasal Biopsy in Subjects \>18 Years of Age with Perennial Allergic Rhinitis (PAR)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
125
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Nijmegen, Netherlands
GSK Investigational Site
The Hague, Netherlands
Quantitative and qualitative differences in the morphology and cytology of the nasal mucosa after 1 year of treatment.
No Secondary Outcome Measures
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.